Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Decision Due Next Month On Job-Creating EU SPC Manufacturing Waiver

Executive Summary

A decision is due to be taken next month on whether to go ahead with a proposal for an EU supplementary protection certificate manufacturing waiver that could create thousands of new manufacturing jobs in the generics and biosimilars industry and increase competition on the European market.

You may also be interested in...

EU SPC Waiver Move Puts Originator And Generic/Biosimilar Firms At Odds

A European Commission legislative proposal to change the EU’s rules on supplementary protection certificates and allow for the production of versions of patent-protected medicines for sale outside the EU has been welcomed by the generics and biosimilars industry – albeit with caveats – but criticized by the originator industry as an attack on intellectual property that could hit investment in Europe.

Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants

Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.

Russia’s Sputnik V COVID-19 Vaccine Starts EU Rolling Review

The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts